^
Association details:
| Biomarker: | BAIAP2-ROS1 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report
Published date:
07/28/2022
Excerpt:
...we identified a novel BAIAP2-ROS1 fusion in a 71-year-old non-smoking female patient with stage IVB lung adenocarcinoma….The patient subsequently received crizotinib and showed significant tumor reduction until 17 months, who got benefit from targeted therapy.
DOI:
https://doi.org/10.2147/OTT.S372134
